Allison Gatlin's profile photo

Allison Gatlin

California

Tech Reporter and New America Editor at Investor's Business Daily

Biopharma and medtech reporter for Investor's Business Daily, @IBDinvestors. @Cronkite_ASU alumna, taco connoisseur and twin mom. She/her.

Featured in: Favicon investors.com Favicon usatoday.com Favicon yahoo.com (+3) Favicon chicagotribune.com Favicon csmonitor.com Favicon flipboard.com Favicon nasdaq.com Favicon orlandosentinel.com Favicon dailypress.com Favicon bakersfield.com

Articles

  • Sarepta Therapeutics Plummets 43% After A Second Gene Therapy Recipient Dies

    1 week ago | inkl.com | Allison Gatlin

    Sarepta stock plummeted Monday after the company said a second patient died following treatment with its Duchenne muscular dystrophy gene therapy, Elevidys. Similar to the first patient, a 16-year-old who could no longer walk, the second death occurred in a non-ambulatory patient. Both developed acute liver failure after receiving Sarepta Therapeutics' approved gene therapy.

  • Sage Therapeutics Snapped Up In Deal Worth Up To $561 Million

    1 week ago | investors.com | Allison Gatlin

    Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning.

  • Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million

    1 week ago | inkl.com | Allison Gatlin

    Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal worth up to $561 million. The news sent Sage stock flying more than 34% to 9, while Supernus stock rose 3.3% to 33.07. Supernus Pharma sells treatments for epilepsy, migraine, Parkinson's disease and attention deficit hyperactivity disorder, or ADHD. Acquiring Sage expands the company's presence in nonpsychiatric conditions.

  • Insmed Stock Catapults On A 'Home Run' Vs. Rivals United, Liquidia

    2 weeks ago | investors.com | Allison Gatlin

    Insmed (INSM) stock catapulted into breakout territory early Tuesday after the biotech company hit a "home run" with its treatment for pulmonary arterial hypertension. Pulmonary arterial hypertension, or PAH, is a form of high blood pressure in the arteries of the lungs. Its symptoms are progressive and can include shortness of breath, fatigue, dizziness, chest pain and swelling of the extremities. Insmed's drug is an inhaled powder called treprostinil palmitil.

  • Vaccine Stocks Hit After RFK Jr. Guts CDC's Vaccine Committee

    2 weeks ago | investors.com | Allison Gatlin

    Vaccines stocks slipped late Monday — led by Moderna (MRNA) — after Health Secretary Robert F.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
7K
Tweets
10K
DMs Open
Yes
Allison Gatlin
Allison Gatlin @IBD_AGatlin
3 Oct 22

Two of the best-rated biotech stocks are also among the worst performers today. Here's why. $APLS $BLTE https://t.co/riqaFbn0gO

Allison Gatlin
Allison Gatlin @IBD_AGatlin
23 Aug 22

When you email a PR person ENDLESSLY about a specific topic... only to see him quoted in another publication about said topic (after ghosting you for a month). Yes, this is a subtweet. Yes, I'm bitter.

Allison Gatlin
Allison Gatlin @IBD_AGatlin
22 Aug 22

Highly rated $SGFY and $PRVA surged today on news $AMZN, $UNH, $CVS and $OPCH. https://t.co/caicsaopHy